Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Capmatinib is a targeted therapy for patients with non-small cell lung cancer with specific gene mutations, with significant efficacy and a relatively good safety profile.What is t···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：355
Capmatinib is an oral drug manufactured by Novartis Pharmaceutical. It is a tyrosine kinase inhibitor that specifically targets the c-Met receptor. Capmatinib has shown durable eff···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：298
Capmatinib inhibits the growth of cancer cells caused by specific genetic variants, i.e., MET exon 14 skipping or MET amplification. These genetic variants are common in tumors suc···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：348
The price of Exkivity varies depending on a number of factors, including the version of the drug (innovator or generic), manufacturer, sales channel, and regional policies.Is Exkiv···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：274
Exkivity is an orally targeted drug targeting EGFR gene mutations for the treatment of patients with non-small cell lung cancer who have not been treated with EGFR-targeted drugs a···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：306
Exkivity is a targeted therapy for specific types of non-small cell lung cancer (NSCLC). Prices vary by region, sales channel, and version (innovator or generic).How much is a box ···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：308
Exkivity is a targeted drug for the treatment of specific types of lung cancer, specifically developed for the treatment of patients with non-small cell lung cancer (NSCLC) harbori···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：359
Exkivity is available in multiple versions, including innovator versions and multiple generic versions. These versions may vary based on factors such as different manufacturers, dr···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：316
Exkivity, also known as Mobocertinib, is a novel targeted drug that offers hope to patients with specific types of lung cancer. The launch of Exkivity marks a major step forward in···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：362
Capmatinib inhibits MET phosphorylation by hepatocyte growth factor binding or triggered by MET amplification, as well as MET-mediated phosphorylation of downstream signaling prote···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：252
Fidaxomicin is prescribed for the management of Clostridium difficile associated diarrhea in individuals aged 6 months and beyond. It is imperative for patients to remain vigilant ···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：288
Fidaxomicin received its initial approval from the Food and Drug Administration (FDA) in the United States in 2011 and has since been effectively commercialized. This article serve···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：302
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3372025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3272025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：3012025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
